US EditionNovo Nordisk ends deal with Hims & Hers over sales of Wegovy copycats; HIMS drops 20%
- On June 23, 2025, Novo Nordisk ended its marketing deal with Hims & Hers Health over concerns about deceptive promotion of cheaper knock-off Wegovy drugs in the U.S.
- The termination followed the FDA's resolution of the Wegovy shortage in late April and Novo Nordisk's claim that Hims violated laws banning mass sales of compounded drugs disguised as personalized treatments.
- Novo Nordisk accused Hims & Hers of risking patient safety by selling illegitimate semaglutide drugs containing unapproved ingredients from foreign suppliers not inspected or authorized by the FDA.
- Shares of Hims & Hers dropped nearly 30% in morning trading on the news, while Novo Nordisk pledged to protect patients and maintain Wegovy access through other trusted telehealth partners.
- The split highlights regulatory challenges in the obesity drug market, which analysts predict could surpass $150 billion globally by 2035 and remain highly competitive amid quality and safety concerns.
79 Articles
79 Articles
HIMS & HERS HEALTH INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick ...
NEW YORK and NEW ORLEANS, June 24, 2025 (GLOBE NEWSWIRE) -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), is investigating claims on behalf of…
HIMS & HERS HEALTH INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates Claims on Behalf of Investors of Hims & Hers Health, Inc. - HIMS - Hims & Hers Health (NYSE:HIMS)
NEW YORK and NEW ORLEANS, June 24, 2025 (GLOBE NEWSWIRE) -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), is investigating claims on behalf of investors of Hims & Hers Health, Inc. ("Hims" or the "Company") (NYSE:HIMS). The investigation concerns whether Hims & Hers Health and certain of its officers and/or directors have engaged in fraud, negligence or other unlawf…
The recent break between Hims & Hers and Novo Nordisk led to a 35% sharp fall in Hims & Hers shares.According to the original report, Novo Nordisk, the Danish pharmaceutical giant, decided to terminate his agreement because Hims promoted a more economical version of his popular weight loss drug, Wegovy.Accusations and ControversiesThe situation escalated quickly after Novo Nordisk accused Hims of violating laws by selling massively composite dru…
Coverage Details
Bias Distribution
- 58% of the sources are Center
To view factuality data please Upgrade to Premium
